Pragmatica-Lung Tests a Treatment and a New Approach to Trials

The newly opened Pragmatica-Lung trial compares ramucirumab plus pembrolizumab versus usual care for treatment of stage IV or recurrent non-small cell lung cancer. The trial is designed to ease enrollment requirements and data collection needs, focusing on the key endpoint of overall survival. Listen as study lead Karen Reckamp, MD, professor and division director for Cedar Sinai Cancer and Medical Oncology, and Bob Figlin, MD, the Steven Spielberg Family Chair in hematology oncology at Cedar Sinai Cancer, talk about how the trial came about and why it could change how future studies are done across cancer types